Incretins in the treatment of type 2 diabetes mellitus Tip 2 diabetes mellitus tedavisinde inkretinler

Creative Commons License

Çolak R.

Ondokuz Mayis Universitesi Tip Dergisi, cilt.29, ss.30-38, 2012 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29
  • Basım Tarihi: 2012
  • Doi Numarası: 10.5835/jecm.omu.29.s1.007
  • Dergi Adı: Ondokuz Mayis Universitesi Tip Dergisi
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.30-38
  • Anahtar Kelimeler: Diabetes mellitus, DPP-4 inhibitors, Exenatide, GLP-1 analogues, Incretins, Liraglutide
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Incretin hormones are defined as intestinal hormones released in response to nutrient ingestion. The incretin hormones include glucagon-like peptide (GLP-l) and glucose dependent polypeptide (GIP). GLP-l secreted by L cells from ileum and colon while GIP is maily produced K cells from the upper small intestine. Incretin hormones potentiate the glucose induced insulin response from pancreatic beta cells. With their non weight-gain, non hypoglycemic attributes and with positive effects on beta cell mass and lifetime as proven by animal experiments, parenterally used GLP-1 agonists of Exenatide and Liraglutide have emerged among medications used for the treatment of early stage diabetes. Dipeptidyl peptidase-4 inhibitors are effective either as a single or combination therapy in lowering glycated hemoglobin, fasting and postprandial glucose levels, with a low incidence of hypoglycemia and no weight gain.